ZL-1503

Phase 1Small molecule

ZZai Lab (Shanghai) Co., Ltd.

ZL-1503 is one of 3 small molecule programs targeting Atopic Dermatitis (AD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic Dermatitis (AD)Recruiting

Atopic Dermatitis (AD)Phase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Atopic Dermatitis (AD)

#DrugCompanyPhaseTrials

ENV-294

EEnveda Therapeutics

Phase 2

1 2

BFB759

BBluefin Biomedicine, Inc.

Phase 2

1 3

ZL-1503

ZZai Lab (Shanghai) Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Study completion

NCT07658482

Phase 1Recruiting

Atopic Dermatitis (AD)

NCT07235384

Clinical

Trials by Indication[1]

Atopic Dermatitis (AD)1 trial

A Phase 1/1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT07235384·84 enrolled

Unspecified1 trial

A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-1503 Following a Single Dose of Subcutaneous or Intravenous Administration in Healthy Volunteers.

Not yet recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT07658482·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ZL-1503. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-1503 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZL-1503. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZai Lab (Shanghai) Co., Ltd.

ZL-1503

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Atopic Dermatitis (AD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News